83 results
Approved WMOPending
Participants enrolling from study CLNP023B12301 or CLNP023B12302• Primary Objective: To evaluate the long-term safety and tolerability of iptacopan in participants with C3G or IC-MPGN
Approved WMORecruiting
Primary objective adults:To demonstrate the superiority of iptacopan (200 mg b.i.d.) compared to placebo in reducing proteinuria at 6 months of treatment.The primary clinical question of interest is:What is the effect of iptacopan vs. placebo on log…
Approved WMOPending
The primary objective is to evaluate the long-term safety and tolerability of iptacopan in eligible participants. The primary clinical question of interest is: what is the long-term safety and tolerability of iptacopan in IgAN participants including…